Experiment 68640

Compounds isolated

Details

PropertyValue
Pharmacology
Administration routeORAL
OrganismEmpty organism
CitationWILKINSON,D: MURRAY,J:. (2001). GALANTAMINE: A RANDOMIZED,DOUBLE-BLIND,DOSE COMPARISON IN PATIENTS WITH ALZHEIMER'S DISEASE.. 16(9)
Amount utilized
Compound isolated
DiseaseTO INVESTIGATE WHETHER GALANTAMINE SIGNIFICANTLY IMPROVES THE CORE SYMPTOMS OF ALZHEIMER'S DISEASE (AD).METHOD A MULTICENTRE, RANDOMIXED, PARALLEL, DOUBLE-BLIND,PLACEBO-CONTROLLED TRIAL WAS CARRIED OUT TO EVALUATE THE EFFICACY AND TOLERABILITY O GALANTAMINE 18,24 MG/DAY ADMINISTERED FOR 3 MONTHS IN 285 PATIENTS WITH MILD-TO-MODERATE PROBABLE AD. RESULTS: PATIENTS TREATED WITH GALANTAMINE 24 MG/DAY HAD A SIGNIFICANTLY BETTER OUTCOME THAN PLACEBO ON ADAS-CO;THIS STUDY SHOWS THEAT , RELATI TO PLACEBO, GALANTAMINE SIGNIFICANTLY IMPROVES THE CORE SYMPTOMS OF ALZHEIMER'S DISEASE.
Dose amountVAR
Number1
Qualitative resultACTIVE
AnimalHUMAN ADULT
Dose expressionDOSE
GenderGIVEN TO BOTH SEXES